Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.02 - $3.02 $87,292 - $130,506
43,214 New
43,214 $115,000
Q2 2023

Aug 14, 2023

SELL
$1.2 - $1.76 $59,347 - $87,042
-49,456 Reduced 40.54%
72,525 $100,000
Q1 2023

May 15, 2023

BUY
$1.46 - $7.3 $54,066 - $270,333
37,032 Added 43.59%
121,981 $194,000
Q4 2022

Feb 14, 2023

BUY
$5.09 - $8.5 $68,740 - $114,792
13,505 Added 18.9%
84,949 $529,000
Q3 2022

Nov 14, 2022

BUY
$5.45 - $8.13 $139,231 - $207,697
25,547 Added 55.66%
71,444 $479,000
Q2 2022

Aug 15, 2022

SELL
$4.77 - $6.67 $127,010 - $177,602
-26,627 Reduced 36.71%
45,897 $292,000
Q1 2022

May 16, 2022

BUY
$3.34 - $5.56 $561 - $934
168 Added 0.23%
72,524 $337,000
Q4 2021

Feb 14, 2022

BUY
$4.81 - $11.92 $8,585 - $21,277
1,785 Added 2.53%
72,356 $362,000
Q3 2021

Nov 15, 2021

BUY
$11.34 - $21.37 $467,627 - $881,234
41,237 Added 140.58%
70,571 $850,000
Q1 2021

May 17, 2021

SELL
$25.12 - $36.89 $237,283 - $348,462
-9,446 Reduced 24.36%
29,334 $823,000
Q4 2020

Feb 16, 2021

BUY
$24.2 - $35.76 $711,988 - $1.05 Million
29,421 Added 314.36%
38,780 $1.01 Million
Q3 2020

Nov 16, 2020

BUY
$31.18 - $52.71 $291,813 - $493,312
9,359 New
9,359 $348,000
Q3 2019

Nov 14, 2019

SELL
$34.47 - $47.53 $340,908 - $470,071
-9,890 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$40.1 - $52.33 $190,354 - $248,410
4,747 Added 92.3%
9,890 $460,000
Q1 2019

May 15, 2019

SELL
$40.11 - $53.57 $221,848 - $296,295
-5,531 Reduced 51.82%
5,143 $206,000
Q4 2018

Feb 14, 2019

BUY
$36.99 - $59.11 $394,831 - $630,940
10,674 New
10,674 $491,000
Q4 2017

Feb 14, 2018

SELL
$43.47 - $67.43 $1.87 Million - $2.9 Million
-42,954 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$43.8 - $52.77 $1.88 Million - $2.27 Million
42,954
42,954 $2.15 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $160M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.